Citadel Advisors’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-3,218,810
| Closed | -$170M | – | 14832 |
|
|
2026
Q1 | $170M | Buy |
3,218,810
+52,168
| +2% | +$2.14M | 0.03% | 520 |
|
|
2025
Q4 | $128M | Buy |
3,166,642
+1,577,308
| +99% | +$36.5M | 0.02% | 709 |
|
|
2025
Q3 | $11.9M | Sell |
1,589,334
-2,309,677
| -59% | -$14.7M | ﹤0.01% | 3001 |
|
|
2025
Q2 | $14.5M | Sell |
3,899,011
-8,876
| -0.2% | -$27.7K | ﹤0.01% | 2552 |
|
|
2025
Q1 | $10.8M | Buy |
3,907,887
+640,108
| +20% | +$2.61M | ﹤0.01% | 2752 |
|
|
2024
Q4 | $18.1M | Sell |
3,267,779
-405,447
| -11% | -$2.75M | ﹤0.01% | 2272 |
|
|
2024
Q3 | $30.6M | Buy |
3,673,226
+2,213,276
| +152% | +$18.2M | 0.01% | 1661 |
|
|
2024
Q2 | $9.94M | Sell |
1,459,950
-1,505,636
| -51% | -$9.12M | ﹤0.01% | 2782 |
|
|
2024
Q1 | $19.5M | Buy |
2,965,586
+2,930,946
| +8,461% | +$19.1M | ﹤0.01% | 2100 |
|
|
2023
Q4 | $225K | Sell |
34,640
-41,102
| -54% | -$217K | ﹤0.01% | 9706 |
|
|
2023
Q3 | $381K | Buy |
75,742
+74,286
| +5,102% | +$471K | ﹤0.01% | 8662 |
|
|
2023
Q2 | $12.7K | Sell |
1,456
-390,609
| -100% | -$4.55M | ﹤0.01% | 13065 |
|
|
2023
Q1 | $4.64M | Sell |
392,065
-123,732
| -24% | -$1.18M | ﹤0.01% | 3942 |
|
|
2022
Q4 | $5.25M | Buy |
+515,797
| New | +$3.43M | ﹤0.01% | 3776 |
|
|
2022
Q3 | – | Sell |
-38,810
| Closed | -$96K | – | 13598 |
|
|
2022
Q2 | $96K | Buy |
+38,810
| New | +$77.5K | ﹤0.01% | 11450 |
|
|
2021
Q3 | – | Sell |
-18,200
| Closed | -$223K | – | 14641 |
|
|
2021
Q2 | $223K | Sell |
18,200
-14,421
| -44% | -$246K | ﹤0.01% | 11926 |
|
|
2021
Q1 | $718K | Buy |
+32,621
| New | +$715K | ﹤0.01% | 8885 |
|
Other funds holding TERN
Citadel Advisors's TERN Position: Q2 2026 in Review
Citadel Advisors sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 3,218,810 shares — an estimated $170M sold.
Citadel Advisors first reported a position in TERN in Q1 2021 and held it in 17 quarters. The position peaked at $170M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Citadel Advisors reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 3,218,810 Terns Pharmaceuticals shares in Q2 2026, an estimated $170M.
- Citadel Advisors first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 17 quarters.
- Citadel Advisors's Terns Pharmaceuticals position peaked at $170M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.